CTHRC1 is associated with BRAF(V600E) mutation and correlates with prognosis, immune cell infiltration, and drug resistance in colon cancer, thyroid cancer, and melanoma

被引：0
|
作者：
Zhang, Rumeng [1 ]
Wang, Zhihao [2 ]
Wang, Huan [3 ]
Li, Lin [2 ]
Dong, Lin [2 ]
Ding, Lin [2 ]
Li, Qiushuang [4 ]
Zhu, Linyan [2 ]
Zhang, Tiantian [4 ]
Zhu, Yong [4 ]
Ding, Keshuo [2 ,5 ]
机构：
[1] Anhui Med Univ, Sch Basic Med Sci, Dept Pharmacol, Hefei, Anhui, Peoples R China
[2] Anhui Med Univ, Sch Basic Med Sci, Dept Pathol, Hefei, Anhui, Peoples R China
[3] Anhui Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Hefei, Anhui, Peoples R China
[4] Anhui Med Univ, Sch Basic Med Sci, Dept Pathophysiol, Hefei, Peoples R China
[5] Anhui Med Univ, Affiliated Hosp 1, Dept Pathol, Hefei, Anhui, Peoples R China
来源：
BIOMOLECULES AND BIOMEDICINE | 2024年 / 25卷 / 01期
关键词：
Collagen triple helix repeat containing 1 (CTHRC1); BRAF(V600E); colon cancer; thyroid cancer; melanoma; MELANOCYTIC NEVI; VEMURAFENIB; EXPRESSION; OVEREXPRESSION; BIOMARKER; INVASION; PATHWAY; MARKER; GROWTH; PD-1;
D O I：
10.17305/bb.2024.10397
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Colon cancer, thyroid cancer, and melanoma are common malignant tumors that seriously threaten human health globally. The B-Raf proto-oncogene, serine/threonine kinase (BRAF)(V600E) mutation is an important driver gene mutation in these cancer types. In this study, we identified that collagen triple helix repeat containing 1 (CTHRC1) expression was associated with the BRAF(V600E) mutation in colon cancer, thyroid cancer, and melanoma. Based on database analysis and clinical tissue studies, CTHRC1 was verified to correlate with poor prognosis and worse clinicopathological features in colon cancer and thyroid cancer patients, but not in patients with melanoma. Several signaling pathways, immune cell infiltration, and immunotherapy markers were associated with CTHRC1 expression. Additionally, a high level of CTHRC1 was correlated with decreased sensitivity to antitumor drugs (vemurafenib, PLX-4720, dabrafenib, and SB-590885) targeting the BRAF(V600E) mutation. This study provides evidence of a significant correlation between CTHRC1 and the BRAF(V600E) mutation, suggesting its potential utility as a diagnostic and prognostic biomarker in human colon cancer, thyroid cancer, and melanoma.
引用
收藏
页码：42 / 61
页数：20
相关论文
共 50 条
  • [41] The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
    Farina-Sarasqueta, A.
    van Lijnschoten, G.
    Moerland, E.
    Creemers, G. -J.
    Lemmens, V. E. P. P.
    Rutten, H. J. T.
    van den Brule, A. J. C.
    ANNALS OF ONCOLOGY, 2010, 21 (12) : 2396 - 2402
  • [42] BRAF V600E mutation in childhood Langerhans cell histiocytosis correlates with multisystem disease and poor survival
    Bhatia, Prateek
    Singh, Minu
    Sharma, Madhulika
    Sharma, Ajay
    Kakkar, Nandita
    Radhika, S.
    Trehan, Amita
    Bansal, Deepak
    BLOOD CELLS MOLECULES AND DISEASES, 2020, 82
  • [43] BRAF V600E Mutation in Colorectal Cancer Is Associated with Right-sided Tumours and Iron Deficiency Anaemia
    Sideris, Michail
    Adams, Katie
    Moorhead, Jane
    Diaz-Cano, Salvador
    Bjarnason, Ingvar
    Papagrigoriadis, Savvas
    ANTICANCER RESEARCH, 2015, 35 (04) : 2345 - 2350
  • [44] Comparative efficiency of differential diagnostic methods for the identification of BRAF V600E gene mutation in papillary thyroid cancer (Review)
    Liu, Qian
    Jiang, Xue
    Tu, Wenling
    Liu, Lina
    Huang, Ying
    Xia, Yuxiao
    Xia, Xuliang
    Shi, Yuhong
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2024, 27 (04)
  • [45] Promoter methylation of Wnt5a is associated with microsatellite instability and BRAF V600E mutation in two large populations of colorectal cancer patients
    Rawson, J. B.
    Mrkonjic, M.
    Daftary, D.
    Dicks, E.
    Buchanan, D. D.
    Younghusband, H. B.
    Parfrey, P. S.
    Young, J. P.
    Pollett, A.
    Green, R. C.
    Gallinger, S.
    McLaughlin, J. R.
    Knight, J. A.
    Bapat, B.
    BRITISH JOURNAL OF CANCER, 2011, 104 (12) : 1906 - 1912
  • [46] HI-511 overcomes melanoma drug resistance via targeting AURKB and BRAF V600E
    Chang, Xiaoyu
    Zhang, Tianshun
    Wang, Qiushi
    Rathore, Moeez Ghani
    Reddy, Kanamata
    Chen, Hanyong
    Shin, Seung Ho
    Ma, Wei-ya
    Bode, Ann M.
    Dong, Zigang
    THERANOSTICS, 2020, 10 (21): : 9721 - 9740
  • [47] AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma
    W Hu
    L Jin
    C C Jiang
    G V Long
    R A Scolyer
    Q Wu
    X D Zhang
    Y Mei
    M Wu
    Cell Death & Disease, 2013, 4 : e914 - e914
  • [48] RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer
    Matsumoto, Akio
    Shimada, Yoshifumi
    Nakano, Mae
    Oyanagi, Hidehito
    Tajima, Yosuke
    Nakano, Masato
    Kameyama, Hitoshi
    Hirose, Yuki
    Ichikawa, Hiroshi
    Nagahashi, Masayuki
    Nogami, Hitoshi
    Maruyama, Satoshi
    Takii, Yasumasa
    Ling, Yiwei
    Okuda, Shujiro
    Wakai, Toshifumi
    ONCOLOGY REPORTS, 2020, 43 (06) : 1853 - 1862
  • [49] TMUB1 expression is associated with the prognosis of colon cancer and immune cell infiltration
    Lu, Yan
    Wang, Kang
    Peng, Yuanhong
    Zhang, Jun
    Ju, Qinuo
    Xu, Qihuan
    Ouyang, Manzhao
    He, Zhiwei
    PEERJ, 2023, 11
  • [50] Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation
    Combe, Pierre
    Chauvenet, Laure
    Lefrere-Belda, Marie-Aude
    Blons, Helene
    Rousseau, Caroline
    Oudard, Stephane
    Pujade-Lauraine, Eric
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (06) : 1267 - 1270
12345